1. Home
  2. MBX vs ITIC Comparison

MBX vs ITIC Comparison

Compare MBX & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBX
  • ITIC
  • Stock Information
  • Founded
  • MBX 2018
  • ITIC 1972
  • Country
  • MBX United States
  • ITIC United States
  • Employees
  • MBX N/A
  • ITIC N/A
  • Industry
  • MBX
  • ITIC Specialty Insurers
  • Sector
  • MBX
  • ITIC Finance
  • Exchange
  • MBX NYSE
  • ITIC Nasdaq
  • Market Cap
  • MBX 379.7M
  • ITIC 440.1M
  • IPO Year
  • MBX 2024
  • ITIC N/A
  • Fundamental
  • Price
  • MBX $9.63
  • ITIC $203.03
  • Analyst Decision
  • MBX Strong Buy
  • ITIC
  • Analyst Count
  • MBX 5
  • ITIC 0
  • Target Price
  • MBX $37.40
  • ITIC N/A
  • AVG Volume (30 Days)
  • MBX 217.8K
  • ITIC 85.6K
  • Earning Date
  • MBX 08-16-2025
  • ITIC 08-05-2025
  • Dividend Yield
  • MBX N/A
  • ITIC 0.91%
  • EPS Growth
  • MBX N/A
  • ITIC 18.56
  • EPS
  • MBX N/A
  • ITIC 15.69
  • Revenue
  • MBX N/A
  • ITIC $261,197,999.00
  • Revenue This Year
  • MBX N/A
  • ITIC N/A
  • Revenue Next Year
  • MBX N/A
  • ITIC N/A
  • P/E Ratio
  • MBX N/A
  • ITIC $12.87
  • Revenue Growth
  • MBX N/A
  • ITIC 15.27
  • 52 Week Low
  • MBX $4.81
  • ITIC $173.29
  • 52 Week High
  • MBX $27.50
  • ITIC $290.40
  • Technical
  • Relative Strength Index (RSI)
  • MBX N/A
  • ITIC 39.07
  • Support Level
  • MBX N/A
  • ITIC $198.43
  • Resistance Level
  • MBX N/A
  • ITIC $207.32
  • Average True Range (ATR)
  • MBX 0.00
  • ITIC 7.61
  • MACD
  • MBX 0.00
  • ITIC 0.34
  • Stochastic Oscillator
  • MBX 0.00
  • ITIC 29.00

About MBX MBX BIOSCIENCES INC

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

About ITIC Investors Title Company

Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.

Share on Social Networks: